CDX
Hep G2
Tumor indication
Hepatocellular Carcinoma
Tumor subtype
Hepatoblastoma
Description
Hep G2 (Liver Cancer CDX Model)
The Hep G2 liver cancer cell line was derived from a 15-year-old patient with hepatocellular carcinoma. It retains many metabolic functions of normal hepatocytes, making it a unique HCC model. Hep G2 is widely used in drug metabolism, toxicity, and cancer research. Its stable biology makes it a key preclinical tool.
Key Features:
- Derived from hepatocellular carcinoma.
- Retains hepatocyte metabolic activity.
- Produces alpha-fetoprotein (AFP).
- Tumorigenic in xenograft systems.
Applications:
Hep G2 is used in HCC therapeutic testing and biomarker validation. It is also applied in liver function and toxicity studies due to preserved metabolic traits. Researchers use it for mechanistic studies of liver cancer progression. Its versatility spans oncology and pharmacology research.
Details
- Tumor indication
- Hepatocellular Carcinoma
- Tumor subtype
- Hepatoblastoma
- Organism
- Human
- Mouse sex
- Female
- Lumin data
- RNA-Seq, WES
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.